Eurazeo set to become leading investor in Kurma Partners

pharmafile | September 24, 2021 | News story | Medical Communications  

Eurazeo has announced its intention to raise its stake in Kurma Partners, a French venture capital firm specialising in biotechnology and medical innovation, to 70.6%.

Kurma Partners has nearly €500 million in assets under management and more than 45 investments made since its launch in 2009, which has built up their widely recognised expertise in the financing of innovation in the sectors of healthcare and biotechnology.

Eurazeo has 12% of its private equity assets under management invested in the healthcare sector, and is pursuing reindustrialisation, reshoring, R&D and innovation, and prevention development. They are a major contributor to the innovation of health care systems in France and Europe, and their increased stake in Kurma Partners strengthens Eurazeo’s position as a leading investor in healthcare.

To bolster Kurma’s growth, Eurazeo plans to commit nearly €100 million to its funds. Eurazeo will also provide operational support, along with access to its international network, to help Kurma Partners become a European leader in the area of life science innovation. However, Kurma Partners will retain its management independence and existing team.  

Virginie Morgon, Chief Executive Officer of Eurazeo, said: “Eurazeo is proud to be accompanying the teams at Kurma Partners, whose strong track record attests to their deep level of expertise and knowledge, positioning the firm as one of the most credible players to support the development of the most promising biotech companies in Europe.”

“We are delighted to welcome Eurazeo’s support at this key stage, which will allow us to ramp up our growth by drawing on the Group’s industrial expertise, operational capacities, and international networks,” add Remi Droller, Thierry Laugel and Vanessa Malier, Managing Partners of Kurma Partners.

The transaction is expected to be finalised by the end of 2021, and remains subject to certain conditions, and approval from the French securities regulator.

Lina Adams

Related Content

No items found

Latest content